An Epidermal Microfluidic Screening Panel for Diabetes Mellitus Related Disorders

用于糖尿病相关疾病的表皮微流体筛查小组

• 批准号: 10248873
• 负责人: Tyler Ray
• 金额: $ 27.43万
• 依托单位: UNIVERSITY OF HAWAII AT MANOA
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-01 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10248873
• 关键词: Acute; Affect; Biochemical; Biochemical Markers; Biological Assay; Biological Markers; Biophysics; Cardiovascular Diseases; Centers of Research Excellence; Chronic Kidney Failure; Clinical assessments; Cognitive; Collection; Cystic Fibrosis; Diabetes Mellitus; Diagnostic; Disease; Disease Progression; Drug usage; Electrolytes; Fatigue; Glucose; Health; Health Status; Home environment; Hormones; Hypertension; Individual; Inflammatory; Intervention; Measurement; Mental Depression; Methods; Microfluidics; Monitor; Neuropathy; Non-Insulin-Dependent Diabetes Mellitus; Outcome; Pathology; Proteins; Standardization; Stress; System; Time; Work; comorbidity; eccrine; flexible electronics; improved; instrumentation; novel; patient population; screening panel; tool; wearable sensor technology

Diabetes Mellitus (DM) is a common, multifaceted condition affecting a vast number of individuals worldwide. Type-2 DM (T2D) comprises an estimated 90% of the patient population and is associated with substantial adverse health outcomes with the most important long-term DM-related disorders comprising chronic kidney disease (CKD), cardiovascular disease, and neuropathy and acute conditions such as ketoacidosis. The lack of facile diagnostic tools for the onset of DM-related comorbidities, particularly CKD and ketoacidosis, imposes intervention and treatment limitations. Although multiple biomolecular and biophysical markers have been proposed for DKD, ketoacidosis, and neuropathy, no standardized method or instrumentation currently exists. There is a critical need for improved measurement methods that will evaluate diabetes associated pathology in the home setting as easily as glucose is presently monitored. Here, the proposed work will develop a novel wearable system that integrates analysis of biochemical markers from eccrine sweat and biophysical activity sensing to establish a DM-relevant screening panel. Sweat contains a wealth of biomarkers relevant to health status, including electrolytes, metabolites, organic compounds, inflammatory/stress biomarkers, proteins and hormones. Aspects of sweat rate and composition have been used in assessing cystic fibrosis, drug use, physical fatigue, cognitive state, depression, and hypertension, among other conditions. This fully-integrated system represents a significant step towards improving the clinical assessment of the onset of DM-relevant complications and disease progression. The platform will house multi-use flexible electronics and a network of underlying microfluidic channels and biochemical assays for non-invasive collection and analysis of key sweat biomarkers. The microfluidics portion is a single use substrate that will have onboard colorimetric and electrochemical assays corresponding to identified bioanalytes for real-time analysis. The key biophysical and biochemical parameters monitored correspond to promising indicators of disease states for DKD, ketoacidosis, or neuropathy.

糖尿病(DM)是一种常见的、多方面的疾病，在世界范围内影响着大量的个人。据估计，2型糖尿病(T2D)占患者总数的90%，并与最重要的长期糖尿病相关疾病相关，包括慢性肾脏疾病(CKD)、心血管疾病、神经病变和酮症酸中毒等急性疾病的严重不良健康后果有关。糖尿病相关并发症，特别是慢性肾脏病和酮症酸中毒的发病缺乏简便的诊断工具，这对干预和治疗造成了限制。尽管多个生物分子和生物物理标志物已经被提出用于DKD、酮症酸中毒和神经病，但目前还没有标准化的方法或仪器存在。迫切需要改进的测量方法来评估家庭环境中的糖尿病相关病理，就像目前监测血糖一样容易。 在这里，拟议的工作将开发一种新型的可穿戴系统，该系统集成了来自外分泌汗液的生化标记分析和生物物理活动传感，以建立与DM相关的筛查小组。汗液中含有大量与健康状况有关的生物标记物，包括电解质、代谢物、有机化合物、炎症/应激生物标记物、蛋白质和激素。出汗率和成分方面已被用于评估囊性纤维化、药物使用、身体疲劳、认知状态、抑郁和高血压等情况。这一完全集成的系统代表着朝着改进糖尿病相关并发症和疾病进展的临床评估迈出的重要一步。该平台将容纳多用途灵活的电子设备以及底层微流控通道和生化分析网络，用于非侵入性地收集和分析关键汗液生物标记物。微流控部分是一种一次性使用的底物，它将具有与识别的生物分析物相对应的板载比色和电化学分析，以进行实时分析。监测的关键生物物理和生化参数对应于DKD、酮症酸中毒或神经病的疾病状态的有希望的指标。